The eye, and particularly the retina, has become a favored testing ground for new biologic drugs. How well novel nucleic acid and cellular therapies work in retinal disease could determine their expansion to other indications. Ken Garber reports.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Change history
15 April 2010
In the version of the article originally published, Michael Tolentino was misquoted to the effect that bevasiranib had been shown to persist indefinitely in post-mitotic cells. Tolentino actually stated that the RNA-induced signaling complex persists. The error has been corrected in the HMTL and PDF versions of the article.
References
Brown, D.M. et al. N. Engl. J. Med. 355, 1432–1444 (2006).
Jo, N. et al. Am. J. Pathol. 168, 2036–2053 (2006).
Maguire, A.M. et al. Lancet 374, 1597–1605 (2009).
Nishijima, K. et al. Am. J. Pathol. 171, 53–67 (2007).
Lu, B. et al. Stem Cells 27, 2126–2135 (2009).
Hu, B.Y. et al. Proc. Natl. Acad. Sci. USA 107, 4335–4340 (2010).
Sengupta, N. et al. Mol. Ther. 17, 1594–1604 (2009).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Garber, K. Biotech in a blink. Nat Biotechnol 28, 311–314 (2010). https://doi.org/10.1038/nbt0410-311
Issue Date:
DOI: https://doi.org/10.1038/nbt0410-311
This article is cited by
-
Companies in footrace to deliver RNAi
Nature Biotechnology (2012)
-
Erratum: Biotech in a blink
Nature Biotechnology (2010)
